AP7 Rec'd PCT/PTO 04 JAN 2006

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Express Mail Label Number

Express Mail Label Number

Form PTO (REV 10-9	-1390-MOD U. S 6)	. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER				
TRANSMITTAL LETTER TO THE UNITED STATES		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)					
	DESIGNATED/ELECTED O		Not Yet Assigned				
	CONCERNING A FILING UN	NDER 35 U.S.C. 371	Not Yet Assigned 1563276				
	NATIONAL APPLICATION NO. P04/008464	INTERNATIONAL FILING DATE 28 July 2004 (28.07.04)	PRIORITY DATE CLAIMED 29 July 2003 (29.07.03)				
	TITLE OF INVENTION PROTEIN FROM PHOTOBACTERIUM DAMSELAE AND USE THEREOF						
	CANT(S) FOR DO/EO/US	ISELAE AND USE THEREOF					
	SANTOS ET AL.						
Applica	nt herewith submits to the United States D	esignated/Elected Office (DO/EO/US) the	ne following items and other information:				
<ol> <li>2. □</li> <li>3. □</li> <li>4. ☒</li> <li>5. ☒</li> <li>6. □</li> <li>7. ☒</li> </ol>	<ol> <li>This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>A copy of the International Application as filed (35 U.S.C. 371(c)(2))         <ul> <li>is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> <li>is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </li> <li>A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).</li> <li>are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>have been transmitted by the International Bureau.</li> <li>have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>have not been made and will not be made.</li> </ol>						
10. []	An executed Declaration and Power	of Attorney (original or copy) (35 U.: ternational Preliminary Examination	S.C. 371(c)(4)).				
11. 🛛	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.					
12. 🗌	An assignment document for recording included.	ng. A separate cover sheet in comp	liance with 37 CFR 3.28 and 3.31 is				
13. 🖂	A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelim	ninary amendment.					
14. 🛛	An Application Data Sheet under 37	CFR 1.76.					
15. 🗌	A substitute specification.						
16. 🗌	A change of power of attorney and/or	address letter.					
1.7. 🛛	A computer-readable form of the seq 1.825.	uence listing in accordance with PC	T Rule 13 <i>ter</i> .2 and 37 CFR 1.821-				
18. 🔲	A second copy of the published Intern	national Application under 35 U.S.C	. 154(d)(4).				
19. 🔲	A second copy of the English language	ge translation of the International ap	plication under 35 U.S.C. 154(d)(4).				
20. 🖂	Other items or information: Unexecution	ted Declaration and Post Card.					

Not Yet Assigned 1 5 0 5 2 7 6 PCT/EP04/008464 VA/H		/1A				
The following fees are submitted:		CALCULATI	ONS PTO USE			
21. 🛛 Basic national fee. \$30	0					
22. Examination Fee  If International preliminary examination report was prepared by USPTO	•					
and all claims satisfy provisions of PCT Article 33(1)-(4)						
All other situations\$20	0					
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international						
application to the USPTO as an International Searching Authority \$  ☐ If International Search Report was prepared and provided to the Office \$  ☐ All other situations	0					
TOTAL OF 21, 22 AND 23 =	\$ 1,000					
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence lis program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of papthereof.	ing o	r computer fraction				
Total Sheets Extra sheets Number of each additional 50 or fraction RATE thereof (round up to a whole number)						
- 100 =   /50 =   X \$ 25	0	\$				
Surcharge of \$130 for furnishing the oath of declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$				
CLAIMS NUMBER FILED NUMBER EXTRA RATE						
Total claims         36         - 20         =         16         X         \$         5           Independent claims         7         - 3         =         4         X         \$         20		\$ 800 \$ 800				
Independent claims   7   -3 =   4   X \$ 20  MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 36		\$ 800 \$	-			
TOTAL OF ABOVE CALCULATIONS = \$ 2,600						
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$				
SUBTOTAL  Processing fee of \$130 for furnishing the English translation later than   30 months from the	·=	\$ 2,600				
earliest claimed priority date (37 CFR 1.492(f)).	.	\$				
TOTAL NATIONAL FEE	=	\$ 2,600	-			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompani by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property	ed	\$	i			
TOTAL FEES ENCLOSED	=	\$ 2,600				
		Amount to be: refunded				
	L	charged	\$			
a. A check in the amount of \$ to cover the above fees is enclosed.						
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$2,600 to cover the above fees. A duplicate copy of this form is enclosed.						
c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.						
Send all correspondence to the address associated with Customer No. 001095, which is currently:						
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080  David L. Marks Attorney for Applicants Reg. No. 37,881 (862) 778-7922			<u>*</u>			